Bruker Cellular Analysis provides missing insights into the true in vivo biology (i.e. the phenome) of each cell required to advance discovery to clinical research.

FUNCTIONAL CELL BIOLOGY

The Phenome, Defined

The phenome is the set of all phenotypic traits expressed by a cell or organism, central to all questions in biology, in which the sum of the parts creates a whole.

Each cell has a phenome & is an independent functioning life.

The phenome is the sum of many functions, or collective life, for each cell.

“Life’s definition, as it stands now, is akin to a menu. It is not one thing but a series of things, a set of behaviors, a series of processes, not a single property. To be living, an organism must have the capacity to reproduce, to grow, to metabolize, to adapt to stimuli, and to maintain its internal milieu.”
— Siddhartha Mukherjee, “The Song of the Cell”
Chapter 01 / 04
01
Key Takeaways
The evolution of functional biology has brought us to this current era of the phenome.
Traditional technologies parse individual parts of the phenome but do not provide the whole picture.
Bruker Cellular Analysis empowers researchers to leverage the full potential of each cell and drive the next era of functional biology.
Overview

A New Phenome Defined

The evolution of functional biology began with immune surface breakthroughs and the advent of flow cytometry, which defined CD4 T cells and enhanced the ability to combat infectious diseases. Following this, significant genome breakthroughs led to the ability to change T cell receptors and create novel therapies such as CAR-T. The era of phenome is now upon us as we increase our scope of biological understanding, enabling the engineering of new therapies with optimal functional phenomes.

THE ERA OF THE PHENOME

An Evolution of Biological Breakthroughs:
The Era of the Phenome in Historical Context

The Challenge: A Disconnected View of Biology

A Disconnected View

In particular, today's solutions typically look at three things:

  • Parts of each cell's phenome
  • Across multiple instruments
  • Creating slowness and complexity to leverage the phenome

Bruker Cellular Analysis is Designed to Enable the Next Wave of Biological Breakthroughs

Our technologies uniquely capture aspects of the phenome required to accelerate biological solutions for thousands of labs in this next era of the phenome.

The Bruker Cellular Analysis Suite of discovery to clinical research technologies can capture the phenome, the collective sum of the parts of the cells, the phenotype, and the functional phenotype, and leverage that to pick the best whole cells and pick the best patient response.

Chapter 02 / 04
02
Key Takeaways
Traditional technology misses the critical functional attributes that only Bruker Cellular Analysis' unique highly-functional biology can reveal.
Bruker Cellular Analysis' functional difference uniquely reveals the highly-proteomic and multi-functional immune cells orchestrating immune response.
Potent cells are key predictors of early and persistent response to cancer, vaccine efficacy, and overall survival, as published in various high-impact journals.
Overview

Our Highly-Functional Cells

Bruker Cellular Analysis uniquely reveals Potent and Dysfunctional Cells — highly polyfunctional cells that are early actors and orchestrators in the immune response. These rare subsets of highly functional cells can be beneficial (Potent Cells) or detrimental (Dysfunctional Cells). Detecting these cells is critical for developing more effective immune therapies and vaccines.

Our Most Potent Cells

Bruker Cellular Analysis: Our Most Functionally Powerful Cells, Revealed

Potent Cells

Potent cells are rare subsets of highly-polyfunctional cells that orchestrate the response against tumors and correlate to potency, persistence, and survival.

Dysfunctional Cells

Dysfunctional cells are highly-polyfunctional cells that drive disease progression and correlate to inflammation, toxicity, and resistance.

Why Proteomic Function is Critical to Potent Cells

The proteome is complex and requires direct detection. Dynamic in vivo biology is the captured by the proteome— the key to advancing medicines and diagnostics.

Unique Potent Cells are Key to Fighting Cancer

Bruker Cellular Analysis technology can uniquely reveal highly functional cells — the 5-10% of cells that are early actors of an immune response. We achieve this by detecting each cell's highly multiplexing cytokines, chemokines, and phosphoproteins.

Chapter 03 / 04
03
Key Takeaways
Polyfunctional cells secrete many different cytokines simultaneously and have correlated with outcome in multiple studies.
The Next Wave of Biology & Medicine is the Era of the Phenome — Bruker Cellular Analysis will power all labs across that new frontier.
Overview

Our Leap in Innovation

The IsoSpark's leap in innovation allows researchers to immediately detect the most potent immune cells and leverage that response data for preclinical and translational/clinical research.

The Beacon's breakthrough single-cell functional phenotyping tells you exactly which immune/production cell functionally produces key antibodies/proteins and the receptor/clone data, with the ability to retrieve that live cell.

This leap in innovation allows researchers to immediately detect the most potent cell and leverage it for discovery and bioprocessing.

OUR INNOVATIVE TECHNOLOGY

Why Understanding Single Cell Function is Critical

Cytokine function dictates the response of each cell to the tumor:

  • CD4 T cells: Cytokines orchestrate the rest of the cells to attack the tumor
  • CD8 T cells & NK Cells: Cytokines deliver the payload to the tumor
  • Macrophages & T-Reg: Cytokines drive immune suppression in the tumor
Immune
Cells
Immune
Cells
Tumor

Directly Detect the Potent Functional Phenome of Each Cell

With the leaders from Kite Pharma and NCI: in a 20-patient non-Hodgkin Lymphoma CAR-T study, the frequency of highly functional cells (~20-25%), i.e., High PSI of each CAR-T cell therapy product, predicted response - Flow Cytometry & Bulk ELISA did not. Functional single-cell biology uniquely provides this information and can be targeted to create better products before release.

Directly detect the Best Antibodies and Most Potent Cells

Emergency Use Authorization of AstraZeneca’s Evuseld: Researchers at Vanderbilt used our Optofluidic platform to discover the antibodies from primary human tissues. Patients given a single injection of the antibody treatment were 83% less likely to develop symptomatic cases of the coronavirus than participants who were given a placebo.

In a separate trial, patients with mild-to-moderate COVID-19 who were given one dose of antibody treatment within three days of developing symptoms had a reduced risk of developing severe disease by 88%.

Results published in Nature Medicine.

Directly Discover the B cells Producing the Most Potent Antibodies

Every B cell can produce a unique antibody, and discovering the most potent antibody often requires finding the rate B cell in a highly diverse cell population.

Antibody discovery using the traditional hybridoma approach requires the immortalization of B cells by cell fusion that results in the death of >90% of B cells. This significantly reduces the chances of discovering novel antibodies against difficult targets.

Opto B Discovery workflows on the Beacon systems increase the probability of finding the best antibody by direct functional assessment of antibody products by single B cells.

BRUKER CELLULAR ANALYSIS INNOVATION IN CELLULAR ANALYSIS

The IsoCode Chip

Our proprietary & patented “Proteomic Barcoded” IsoCode Chip, named the Scientist's number #1 innovation, works by detecting 30+ cytokines per cell, measuring the functional phenotype of each immune cell.

This breakthrough technical innovation allows for complete single-cell functional characterization — something that was not possible before.

The OptoSelect Chip

Our OEP fluidics uses light and millions of light-actuated pixels to move individual cells to be isolated, cultured, assayed, and exported. Each cell or clone is imaged and monitored in real-time in a NanoPen™ chamber on our OptoSelect™ chips to provide rich visual data early and often. Our Optofluidic product suite delivers cell processing and deep profiling with more information about cell function than any other technology.

Chapter 03 / 04
03
Key Takeaways
ELISA & Flow Cytometry can estimate a sample's cytokine secretion, but cannot detect the highly functional cell subsets that correlate to in vivo response.
RNA-Seq can estimate function as well, but only shows a 0.4 correlation from RNA to protein.
Only Bruker Cellular Analysis can detect the highly-potent single-cell subsets by capturing the range of cytokines (32+) from each cell.
Overview

What's Unique & Innovative about
Bruker Cellular Analysis Single-Cell Functional Phenotyping?

Unlike Bruker Cellular Analysis, these traditional methods are unable to detect the functional biological drivers that can lead to biomarker breakthroughs.

The Bruker Cellular Analysis Difference
Bruker Cellular Analysis Difference
True cytokines from each cell
TRUE SINGLE T CELL BIOLOGY

Bruker Cellular Analysis's Breakthrough Technology

Our technology addresses the core problem that immune cells, which play a major role in cancer immunology, are heterogenous.

Bruker Cellular Analysis enables researchers to fine-tune their immunotherapeutic candidates and identify what differentiates immune cell potency, cell product toxicity, and functional differences between patient responders and non-responders to immunotherapies.

COMPARISON

Traditional Methods vs Bruker Cellular Analysis

Bulk Serum ELISA Averaging
Bulk Averaging
Traditional Method
Bulk Serum ELISA Averaging

Data shows that the specific cytokines produced by each heterogenous immune cell matters, yet bulk averaging masks these cellular differences.

Bulk ELISA averages serum protein information from all cells. In a variety of immunotherapy trials, stratification of responders from non-responders is not possible with bulk cytokine analysis.

Single Cell Cytokine Specificity
The Bruker Cellular Analysis Difference
Bruker Cellular Analysis
Bruker Cellular Analysis
Our single-cell functional proteomics uniquely reveal correlates that lead to biomarker breakthroughs by detecting what each immune cell secretes in a highly multiplexed manner.
  • Captures the true single-cell protein secretion with 30+ plex full range of function
  • Detects how immune cells proteomically perform amongst a heterogenous system
  • Reveals functional biological drivers that identify patient differences
Flow Cytometry & RNA
Estimates
Traditional Method
Flow Cytometry Based Systems

Flow cytometry “surface phenotypes” for many surface markers or detects a few (1-4) blocked cytokines within the cell without detecting what's truly being secreted.

Blocking cytokines within cells increases the risk of spectral overlap and reduces the ability to multiplex cytokines reliably.

RNA-Seq based methods estimate protein function, yet are not protein measurements, with citations showing 0.4 correlation from RNA to protein1.

Reference [1]: Vogel at al. Nature Reviews Genetics (2012)

True, Highly Multiplexed Cytokines Released
The Bruker Cellular Analysis Difference
Bruker Cellular Analysis
Bruker Cellular Analysis

Our unique functional phenotyping is directly measuring the work performed by each T cell, macrophage, or NK cell.

Each IsoCode Chip is proteomically barcoded to provide a quantitative readout of 32 cytokines per cell.

This unique functional phenotyping provides correlative clinical & pre-clinical immune biomarkers for differentiating mechanistic information in the competitive clinical world of immuno-oncology.

Chapter 04 / 06
04
Key Takeaways
IsoSpeak enables researchers to make sense of complex single-cell data by automatically generating intuitive and meaningful visualizations.
Researches can save precious time by using the in-software sample annotations & project organization for immunotherapy workflows.
IsoSpeak helps you get answers faster, with detailed informatics & statistics on cellular potency and durability, all at your fingertips.
Overview

Single-Cell Cytokine
Visualizations & Insights

IsoSpeak is the first automated informatics suite for advanced, functional, single-cell mapping and visualizations which can reveal correlative insights into true, functional immune biology.

Researchers use IsoSpeak to make sense of complex single-cell data by generating meaningful visualizations with the click of a button.

IsoSpeak's push-button user interface and advanced automation allows users to visualize, target, and utilize data from direct, functional cytokine profiling of single cells.

SOFTWARE

IsoSpeak Data
Visualizations

Researchers can use IsoSpeak to automatically generate a unique set of cellular visualizations, sample annotations, and report-ready single-cell readouts.

Chapter 05 / 06
05
Key Takeaways
We've worked hand-in-hand with the pioneers in immunology to discover correlates that were previously hidden.
Our discoveries continue to be published in leading journals such as Nature, Cancer Discovery, JITC, and Blood.
The IsoLight is the new standard found throughout the most innovative labs around the world.
Overview

Publications

Bruker Cellular Analysis' functional phenotyping is critical to finding what's really happening in patients — as shown in 40+ correlative cancer immunology cases. Our functional phenotypes are illustrating the large patient differences between different types of patient responses that are undetectable on other platforms.

INSIGHTS

Bruker Cellular Analysis is Uniquely Revealing the Biological Drivers of Response and Progression

Bruker Cellular Analysis' functional phenotyping has been published and presented by leaders in various clinical and preclinical studies.

Additionally, we've translated that insight to accelerate pre-clinical development — illustrating large differences leading to choice.

Potency CAR-T Preclinical Discovery Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice JCI Insight , 2021 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Persistence
Potency
CAR-T Preclinical Discovery 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells Journal for Immunotherapy of Cancer, 2021 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Response
Survival
T-Cells Clinical Biomarker Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy Blood Advances, 2021 IsoCode Single-Cell Adaptive Immune: Human PBMC
Potency TILs Manufacturing & Product QC, Clinical Biomarker Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial Nature Medicine, 2021 IsoCode Single-Cell Adaptive Immune: Human T-Cell
Potency CAR-T Manufacturing & Product QC, Clinical Biomarker CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial Nature Medicine, 2021 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Efficacy NK Cells Preclinical Discovery Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation Communications Biology, 2021 IsoCode Single-Cell Adaptive Immune: Human NK Cell
Fitness
Response
T-Cells Preclinical Discovery, Clinical Biomarker Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production Blood, 2021 IsoCode Single-Cell Adaptive Immune: Human PBMC
Response
Survival
T-Cells Clinical Biomarker Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma Journal of Clinical Oncology, 2021 IsoCode Single-Cell Adaptive Immune: Human PBMC
Potency NK Cells Preclinical Discovery Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors Cytotherapy, 2021 IsoCode Single-Cell Adaptive Immune: Human NK Cell
Potency NK Cells Preclinical Discovery NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells Frontiers in Immunology, 2021 IsoCode Single-Cell Adaptive Immune: Human NK Cell
Potency CAR-T Preclinical Discovery Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity Molecular Therapy, 2021 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Potency T-Cells Preclinical Discovery, Clinical Biomarker Use of Multi-Site Radiation Therapy for Systemic Disease Control International Journal of Radiation Oncology, Biology, Physics, 2021 IsoCode Single-Cell Adaptive Immune: Human PBMC
Response T-Cells Clinical Biomarker Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer Clinical Cancer Research, 2020 IsoCode Single-Cell Adaptive Immune: Human PBMC
Potency T-Cells Preclinical Discovery Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice Frontiers in Immunology, 2020 IsoCode Single-Cell Adaptive Immune: Human PBMC
Persistence
Potency
NK Cells Preclinical Discovery Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes in vivo Persistence and Enhances Anti-tumor Activity Cell Stem Cell, 2020 IsoCode Single-Cell Adaptive Immune: Human NK Cell
Potency CAR-T Preclinical Discovery CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression Leukemia, 2020 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Persistence
Potency
CAR-T Preclinical Discovery Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice Gastroenterology, 2020 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Persistence
Potency
T-Cells, NK Cells Preclinical Discovery, Clinical Biomarker Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist Nature Communications, 2020 IsoCode Single-Cell Adaptive Immune: Human PBMC
Potency CAR-T Preclinical Discovery Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma Blood Advances, 2019 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Response CAR-T Clinical Biomarker, Manufacturing & Product QC Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Associate with Clinical Outcomes in NHL Blood, 2018 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Potency T-Cells Preclinical Discovery, Clinical Biomarker A Kinetic Investigation of Interacting, Stimulated T Cells Identifies Conditions for Rapid Functional Enhancement, Minimal Phenotype Differentiation, and Improved Adoptive Cell Transfer Tumor Eradication PLOS One, 2018 IsoCode Single-Cell Adaptive Immune: Human PBMC with PMA & Ionomycin
Cancer
Immunology
Single Cell Solution Cell Type Predictive in Indication & Related Statistics
SC-PFS (H)
T cell (H)
Peg-IL2 in Melanoma pre-clinically.2
SC-PFS (H)
T cell (H)
Melanoma response (ipi/nivo)
P = 0.029
SC-PFS (H)
T cell (H)
AML response in checkpoint.
P = 0.0288
SC-PFS (H)
T cell (H)
Pancreatic cancer survival
P = 0.001
SC-PFS (H)
T cell (H)
Pre-clinical NP cancer vaccine efficacy
P = 0.003
SC-IM (M)
Monocyte (H)
Monocyte Tumor suppression correlates
Cell Therapies
Single Cell Solution Cell Type Predictive in Indication & Related Statistics
SC-PFS (H)
CAR-T (H)
Trimeric CAR in BCMA / Myeloma
SC-PFS (H)
CAR-T (H)
Pre-infusion CAR-T in DLBCL.
P = 0.012
SC-PFS (M)
NK cell (M)
Pre-clinical correlates with in vivo mouse studies in TCR & NK cell Therapy
Immune Inflammation
Single Cell Solution Cell Type Predictive in Indication & Related Statistics
SC-PFI (H)
Monocyte (H)
MS progression.
P = 0.035
SC-PFI (H)
CD34+ (H)
PV vs. ET (myelofibrosis).
P = 0.018
SC-PFI (H)
T cell (H)
Neuroinflammation
PUBLICATIONS

Published in 100+ High-Impact Journals

Our highly functional biology helps researchers around the world change the course of advanced medicines and complex diseases.

Press Type
2022
Press Type

VACCINES & INFECTIOUS DISEASE

Li L et al., "In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals", JCI Insight, 2022

Press Type

CELLULAR AND REGENERATIVE MEDICINE

Fernandez-Yague MA et al., "Analyzing immune response to engineered hydrogels by hierarchical clustering of inflammatory cell subsets", Science Advances, 2022

Press Type

Cancer Immunology

Friedman et al., "Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses", Journal for ImmunoTherapy of Cancer, 2022

Press Type

VACCINES & INFECTIOUS DISEASE

Su Yet al., "Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae", Cell, 2022

Press Type
2021
Press Type

CELLULAR AND REGENERATIVE MEDICINE

Thomas A et al., "Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice", JCI Insight, 2021

Press Type

CELLULAR AND REGENERATIVE MEDICINE

Roselli E et al., "4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells", Journal for ImmunoTherapy of Cancer, 2021

Press Type

Cancer Immunology

Abbas H et al., "Single-cell Polyfunctional Proteomics of CD4 Cells from Patients with AML Predicts Responses to Anti-PD-1-based therapy", Blood Advances, 2021

Press Type

CELLULAR AND REGENERATIVE MEDICINE

Gionet-Gonzales M et al., "Sulfated Alginate Hydrogels Prolong the Therapeutic Potential of MSC Spheroids by Sequestering the Secretome", Advanced Healthcare Materials, 2021

Press Type

Cancer Immunology

Creelan BC et al., "Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial", Nature Medicine, 2021

Press Type

Cellular and Regenerative Medicine

Spiegel JY et al., "CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase I trial", Nature Medicine, 2021

Press Type

Cancer Immunology

Dhar P et al., "Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation", Communications Biology, 2021

Press Type

Cancer Immunology

Dhar P et al., "Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation", Communications Biology, 2021

Press Type

Cancer Immunology

Boklee J et al., "Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production", Blood, 2021

Press Type

Cancer Immunology

Diab A et al., "Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma", Journal of Clinical Oncology, 2021

Press Type

Cellular and Regenerative Medicine

Chockley P et al., "Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors", Cytotherapy, 2021

Press Type

Cancer Immunology

Mahmoud A et al., "Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression", iScience, 2021

Press Type

Cancer Immunology, Cellular and Regenerative Medicine

Ruiz F et al., "Comprehensive Activation Profiling of Tabelecleucel, an Off-The-Shelf, Allogeneic EBV-Specific T-Cell Immunotherapy", Hematological Oncology, 2021

Press Type

Cancer Immunology

Vicioso Y et al., "NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells", Frontiers in Immunology, 2021

Press Type

Vaccines & Infectious Disease

Szabo PA et al., "Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19", Immunity, 2021

Press Type

Cellular and Regenerative Medicine

McKenna MK et al., "Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity", Molecular Therapy, 2021

Press Type

Oncology

Patel RR et al., "Use of Multi-Site Radiation Therapy for Systemic Disease Control", International Journal of Radiation Oncology*Biology*Physics. 2021., 2021

Press Type

Cellular and Regenerative Medicine

Xie CB et al., "Complement‐activated human endothelial cells stimulate increased polyfunctionality in alloreactive T cells", American Journal of Transplantation, 2021

Our Biology

The New Standard in
Single-Cell Biology

We help researchers around the world accelerate the next generation of cancer immunotherapy with functional immunology.

"Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products."
Marco L Davila
Moffitt Cancer Center
"As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that Bruker Cellular Analysis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T therapy before treatment."
Christine Brown
City of Hope
"Current assays that rely on single-plex ELISA or even multiparametric flow cytometry don't give you the level of resolution that the Bruker Cellular Analysis platform can provide."
John Rossi
Kite Pharma
Chapter 04 / 04
04

The Functional Cell Biology Company

Join researchers worldwide using Bruker Cellular Analysis to reclaim lab time, save precious samples, increase efficacy, and cut down therapeutic timelines by a year+.